December 14, 2017 7:52am
The upside is fair-to-middling while the downside experiences the greater numbers
… The question, is it the algorithms terminating at a final ending state?
I believe, the sector is tired thus too erratic
Pre-open indications: 5 BUYs and 0 SELL
Can’t read because of no subscription rights - you’re missing situational awareness and the most trustworthy source of independent insight!
Higher open expected
Dow futures are UP +14% (+34 points) and NASDAQ futures are UP +12% (+8 points)
U.S. stock index futures are set for a positive open on Thursday, after sentiment was boosted by news that the Federal Reserve had hiked interest rates during its December policy meeting.
European stocks remained lower, as investors digested the latest monetary policy decisions by the U.S. Federal Reserve and Bank of England, before another central bank meeting in Europe.
Asian markets closed slightly lower in their first session following the Federal Reserve's <Wednesday> announcement that it raised U.S. interest rates.
Issues that will affect the trading day: stock news, if any will drive sentiment
Data docket: At 8:30 a.m. ET, jobless claims, retail sales and import & export price indexes are all expected to be published. The Flash US composite purchasing managers' index (PMI) is due out at 9:45 a.m. ET, followed by manufacturing and trade inventories at 10 a.m. ET.
Issues on the political front: Politics will be at the back of investors' minds, as markets await any news surrounding tax reform.
Henry’omics:
From Wednesday night’s closing bell post, “…the sector closed up and positive with a 30/10 advance/decline line. The question remains, who is making money in cell and gene therapy? Investment banks and management teams who salaries increase as their company’s share pricing drops like gutter balls. Retail investors are mad as hells as even traders are perplexed by reversals and spurts … As several cell and gene therapy companies popped and flopped following presentations at the American Society of Hematology.”
Stroke the fire of appreciation - VOLUME needs to be lit-up!
How can you spot a true market leader — and weed out the laggards?
Check the Relative Strength (RS) Rating. This telltale metric which ranges from 1 (worst) to 99 (best) measures a stock’s price performance over the last 12 months. Decades of market research show the best stocks tend to have an 80 or better RS Rating as they launch a new climb.
Also keep an eye on the relative strength line, which compares a stock's price performance to that of the S&P 500. An upward trending RS line tells you the stock is outperforming the general market.
It's an ... omen when the line is in or near new high ground at the time of a breakout.<IBD>
The RegMed and cell therapy sector closed POSITIVE on Wednesday. NEGATIVE on Tuesday and Monday, NEUTRAL on Friday and POSITIVE last Thursday.
The cell therapy sector’s record over 5 sessions (of 40 covered companies):
· Wednesday closed POSITIVE with 8 decliners. 30 advancers and 2 flats;
· Tuesday closed NEGATIVE with 27 decliners, 11 advancers and 2 flats;
· Monday closed NEGATIVE with 27 decliners, 12 advancers and 1 flat;
· Friday closed NEUTRAL with 19 decliners, 19 advancers and 2 flats;
· Last Thursday closed POSITIVE with 11 decliners, 24 advancers and 5 flats;
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what are today’s indications?
Watch list:
- The iShares Nasdaq Biotechnology (IBB) is NOT indicating in Thursday’s pre-market;
- The SPDR S&P Biotech ETF (XBI) is NOT indicating in Thursday’s pre-market;
- The Health Care Select Sector SPDR ETF (XLV) is NOT indicating in Thursday’s pre-open;
- The iShares Russell 2000 (IWM) is indicating a POSITIVE +0.15% in Thursday’s pre-open
Companies in my headlights:
bluebird bio (BLUE) closed down -$6.05 to $184.90 after Tuesday’s -$10.85 to $190.95 after Monday’s -$30.95 to $ +$30.65 to $201.80 with 5.12 M shares traded after Friday’s +$3.25 to $171.15 with 727.2 K shares traded <3 month average = 777.4 K shares>. BLUE priced its 3.343 M share offering at $185.00 and counting on a swift close – Maintaining BUY;
Juno Therapeutics (JUNO) closed up +$1.66 to $47.41 after Tuesday’s -$4.49 to $45.75 with 7.31 M shares traded after Monday’s -$8.41 to $50.24 after Friday’s +$1.92 to $58.65 with 2.37 M shares traded <3 month average = 2.28 M shares> after Thursday’s +$2.17 to $56.73 with 1.18 M shares traded after Wednesday’s +$1.36 to $54.56 after last Tuesday’s -$1.46 to $53.20 with 1.45 M shares trading. November started at $78.56 had a high of $82.06 and a low of $68.25 on 11/14 while October ended at $80.90 having started at $89.37. The aftermarket indication is a POSITIVE +$0.09 or +0.19% – Maintaining BUY;
Regenxbio (RGNX) closed up +$1,00 to $28.15 after Monday’s -$2.25 to $27.15 with 407.5 K shares traded after Monday’s -$2.25 to $29.50 after Friday’s +$1.45 to $31.75 with 325.7 K shares traded <3 month average = 368.1 K shares> after Thursday’s +$0.85 to $30.30 with 391.8 K shares traded after Wednesday’s +$1.25 to $29.45 with 198.9 k shares traded <3 month average = 362.9 K shares>. December started out at $28.90 following Novembers end at $28.10 and start at $28.00 with a low of $26.00 and a high of $29.70. On Thursday, The aftermarket indication is a positive +$0.0034 or +0.01%–Maintaining BUY;
ImmunoCellular Therapeutics (IMUC) closed down -$0.0067 to $0.229 and is up in the aftermarket +$0.2091 or (4.66% to $0.43 based on achieving a key milestone in its research-stage Stem-to-T-Cell immuno-oncology program. The milestone represents an important step toward stimulating the patient's immune system to produce an unlimited supply of killer T cells that specifically target and destroy tumor cells with minimal side effects. This approach could be effective in treating many types of cancers – BUY;
VistaGen (VTGN) closed flat at $1.17 and is up +$0.03 or +2.56% to $1.20 after closing a $15 M offering. Cash speaks although I have doubts on their platform – BUY;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
